Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 74365U107 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Janus Henderson Group Ltd. 13G/A Amendment 7 | 8.4% |
8/13/2026
Event 6/30/2026
|
|
|
Millennium Management LLC
13G/A
Amendment 1
|
5.7% |
7/7/2026
Event 7/1/2026
|
|
| Integrated Core Strategies (US) LLC | 5.1% | ||
| Millennium Management LLC | 5.7% | ||
| Millennium Group Management LLC | 5.7% | ||
| Israel A. Englander | 5.7% | ||
| Janus Henderson Group PLC 13G/A Amendment 6 | 9.6% |
5/15/2026
Event 3/31/2026
|
|
| BlackRock, Inc. 13G | 6.3% |
4/27/2026
Event 3/31/2026
|
|
|
Millennium Management LLC
13G
|
5.1% |
3/2/2026
Event 2/25/2026
|
|
| Millennium Management LLC | 5.1% | ||
| Millennium Group Management LLC | 5.1% | ||
| Israel A. Englander | 5.1% | ||
| Janus Henderson Group PLC 13G/A Amendment 5 | 10.0% |
2/17/2026
Event 12/31/2025
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 4.7% |
1/21/2026
Event 12/31/2025
|
|
|
Janus Henderson Group PLC
13G/A
Amendment 4
|
11.0% |
11/14/2025
Event 9/30/2025
|
|
| Janus Henderson Group PLC | 11.0% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 9.3% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 2
|
4.9% |
8/14/2025
Event 6/30/2025
|
|
| RA Capital Management, L.P. | 4.9% | ||
| Peter Kolchinsky | 4.9% | ||
| Rajeev Shah | 4.9% | ||
| RA Capital Healthcare Fund, L.P. | 4.9% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 3
|
10.6% |
8/14/2025
Event 6/30/2025
|
|
| Janus Henderson Group PLC | 10.6% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 9.1% | ||
| BlackRock, Inc. 13G | 5.6% |
7/17/2025
Event 6/30/2025
|
|
|
Janus Henderson Group PLC
13G/A
Amendment 2
|
10.5% |
5/14/2025
Event 3/31/2025
|
|
| Janus Henderson Group PLC | 10.5% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 9.1% | ||
|
Adage Capital Management, L.P.
13G/A
Amendment 1
|
0% |
5/12/2025
Event 3/31/2025
|
|
| Adage Capital Management, L.P. | 0% | ||
| Robert Atchinson | 0% | ||
| Phillip Gross | 0% | ||
| Opaleye Management Inc. 13G/A Amendment 2 | 4.7% |
4/28/2025
Event 3/31/2025
|
|
|
Janus Henderson Group PLC
13G/A
Amendment 1
|
10.3% |
3/7/2025
Event 2/28/2025
|
|
| Janus Henderson Group PLC | 10.3% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 9.1% | ||
| Opaleye Management Inc. 13G/A Amendment 1 | 5.3% |
2/14/2025
Event 12/31/2024
|
|
|
RA Capital Management, L.P.
13G/A
Amendment 1
|
9.9% |
2/14/2025
Event 12/31/2024
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||
|
Janus Henderson Group PLC
13G
|
6.0% |
2/14/2025
Event 12/31/2024
|
|
| Janus Henderson Group PLC | 6.6% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 6.0% | ||
|
Citadel Advisors LLC
13G/A
Amendment 1
|
4.7% |
2/14/2025
Event 12/31/2024
|
|
| Citadel Advisors LLC | 4.6% | ||
| Citadel Advisors Holdings LP | 4.6% | ||
| Citadel GP LLC | 4.6% | ||
| Citadel Securities LLC | 0% | ||
| Citadel Securities Group LP | 0% | ||
| Citadel Securities GP LLC | 0% | ||
| Kenneth Griffin | 4.7% | ||
| Woodline Partners LP 13G/A Amendment 1 | 3.9% |
2/14/2025
Event 12/31/2024
|
|
|
Adage Capital Management, L.P.
13G
|
6.6% |
2/12/2025
Event 12/31/2024
|
|
| Adage Capital Management, L.P. | 6.6% | ||
| Robert Atchinson | 6.6% | ||
| Phillip Gross | 6.6% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 741 | $2.26 k |
| 2026 Q2 | 122 | 46.1 M | $177 M |
| 2026 Q1 | 119 | 45.6 M | $237 M |
| 2025 Q4 | 109 | 39.8 M | $212 M |
| 2025 Q3 | 86 | 26.2 M | $114 M |
| 2025 Q2 | 83 | 29.7 M | $90.1 M |
| 2025 Q1 | 65 | 28.8 M | $124 M |
| 2024 Q4 | 67 | 30.9 M | $163 M |
| 2024 Q3 | 38 | 10.4 M | $19.1 M |
| 2024 Q2 | 43 | 10.4 M | $22.2 M |
| 2024 Q1 | 41 | 4.57 M | $18.3 M |
| 2023 Q4 | 34 | 4.36 M | $8.17 M |
| 2023 Q3 | 33 | 5.12 M | $8.55 M |
| 2023 Q2 | 32 | 5.26 M | $12.5 M |
| 2023 Q1 | 31 | 5.50 M | $16.9 M |
| 2022 Q4 | 34 | 5.51 M | $14.8 M |
| 2022 Q3 | 32 | 5.66 M | $16.9 M |
| 2022 Q2 | 34 | 5.93 M | $18.4 M |
| 2022 Q1 | 36 | 6.50 M | $33.2 M |
| 2021 Q4 | 41 | 7.32 M | $49.5 M |
| 2021 Q3 | 39 | 6.31 M | $43.7 M |
| 2021 Q2 | 44 | 7.53 M | $73.4 M |
| 2021 Q1 | 53 | 8.95 M | $141 M |
| 2020 Q4 | 51 | 8.78 M | $212 M |
| 2020 Q3 | 49 | 9.28 M | $156 M |
| 2020 Q2 | 34 | 3.75 M | $111 M |